Levreg Partners and Kyowa Kirin Revolutionizing Patient Acquisition and Retention with AI

Client Overview

Kyowa Kirin, a global leader in specialty pharmaceuticals, is dedicated to delivering innovative therapies for patients with rare and serious conditions. Among its key assets is Poteligeo®, an oncology treatment indicated for rare forms of cutaneous lymphoma. In an effort to expand its commercial footprint in North America, the organization prioritized the enhancement of patient identification, retention, and healthcare provider (HCP) engagement for Poteligeo. A core objective was the development of a field-ready solution that could be implemented swiftly, cost-effectively, and with measurable impact, empowering field teams to drive meaningful outcomes at the point of care.

The Challenge

Kyowa Kirin’s commercial team faced a critical need for a streamlined, data-driven solution to support the identification of new patients, improve retention of those existing, and accurately identify HCPs most likely to prescribe Poteligeo. Traditional field approaches are inefficient and lack the precision necessary for success in rare disease markets, which require “right message, right time.” To address these gaps, the company required an integrated tool that could seamlessly align with internal systems, deliver actionable insights, and support the strategic objectives of medical affairs, product management, sales, marketing, and executive leadership – in real time.

The Solution: A Custom LLM Engine

Levreg Partners LLP, with over 20 years of AI expertise, collaborated closely with Kyowa Kirin to develop a bespoke large language model (LLM) engine, integrated with voice- and text-enabled commands, tailored for field sales teams. Unlike traditional consulting firms that often require 12+ months and multimillion-dollar budgets, Levreg delivered the solution in under three months at a fraction of the cost.

• Rapid Development: Levreg worked with Kyowa Kirin’s existing vendors, leveraging real-world experience to identify high-impact AI use cases. The LLM was designed to analyze patient and HCP data, enabling sales teams to target ideal candidates for Poteligeo with precision.

• Voice and Text Capabilities: The LLM allowed sales representatives to interact seamlessly in the field, using natural language to access insights on patient profiles, HCP prescribing patterns, and retention strategies.

• Collaboration Across Teams: Levreg engaged Kyowa Kirin’s medical, product, sales, marketing teams, and senior leadership, including Greg Palko, SVP North America Hematology and Oncology Franchise Head, to ensure the solution met strategic objectives.

  
  

Results and Impact

The custom LLM engine is positioned to deliver transformative results within the first year:

• Projected to generate 10-15% in new revenue growth for Kyowa Kirin

• Achieve a 3-4x return on investment (ROI), significantly outperforming industry benchmarks

• Enhance patient identification and retention, improving access to Poteligeo for those in need

• Strengthen relationships with HCPs by providing actionable insights, fostering trust, and collaboration

• Significantly reduce time to prescribe by 20-50%

  
  

Levreg’s solution will not only drive financial success but also create meaningful value for HCPs and patients, ensuring life-saving treatments reach those who need them most.

Client and Partner Testimonials

"Levreg’s ability to deliver a high-impact AI solution in such a short timeframe was remarkable. Their team’s expertise and collaborative approach enabled us to unlock new opportunities for Poteligeo, driving significant value for our patients, HCPs, and business."-- Greg Palko, SVP North America Hematology and Oncology Franchise Head, Kyowa Kirin

"Our partnership with Kyowa Kirin exemplifies Levreg’s commitment to delivering tailored AI solutions that drive real-world impact. By aligning with their teams and leveraging our decades of experience, we created a tool that is transforming their field operations and delivering exceptional ROI."-- Jennifer Valenti, Managing Partner, Levreg Partners LLP

"The success of this project underscores the power of combining deep AI expertise with a client-centric approach. We’re proud to help Kyowa Kirin achieve its goals while making a meaningful difference for patients and HCPs."-- Scott Lee, Managing Partner, Levreg Partners LLP

In Summary

Levreg Partners LLP’s custom LLM engine empowered Kyowa Kirin to overcome critical challenges in patient acquisition and retention for Poteligeo. By delivering a high-impact, cost-effective solution in record time, Levreg demonstrated its ability to drive innovation and value in the pharmaceutical industry. This partnership highlights how strategic AI applications can transform business outcomes while improving access to life-saving treatments.

For additional insights into our collaboration with Kyowa Kirin and the measurable outcomes achieved, we invite you to connect with our team directly at info@levreg.com.